PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis

Journal of Lipid Research

Volumn 45, Issue 12, 2004, Pages 2161-2173

  Li, Andrew C ^a   Glass, Christopher K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Foam cell formation; Liver X receptors; Peroxisome proliferator activated receptors

Indexed keywords

CELL NUCLEUS RECEPTOR; CHOLESTEROL; GLUCOSE; LIPID; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL MATURATION; CHOLESTEROL METABOLISM; FATTY ACID OXIDATION; GENE EXPRESSION REGULATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; DNA-BINDING PROTEINS; HUMANS; LIPID METABOLISM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 10044223533     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.R400010-JLR200     Document Type: Review

References (147)

1. Wilson, J. D. 1990. Charles-Edouard Brown-Sequard and the centennial of endocrinology. J. Clin. Endocrinol. Metab. 71: 1403-1409.
2. Evans, R. M. 1988. The steroid and thyroid hormone receptor superfamily. Science. 240: 889-895.
3. Hennekens, C. H. 1998. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation. 97: 1095-1102.
4. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
5. Glass, C., and J. Witztum. 2001. Atherosclerosis: the road ahead. Cell. 104: 503-516.
6. Gough, P. J., and S. Gordon. 2000. The role of scavenger receptors in the innate immune system. Microbes Infect. 2: 305-311.
7. Boullier, A., D. A. Bird, M. K. Chang, E. A. Dennis, P. Friedman, K. Gillotre-Taylor, S. Horkko, W. Palinski, O. Quehenberger, P. Shaw, D. Steinberg, V. Terpstra, and J. L. Witztum. 2001. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. N. Y. Acad. Sci. 947: 214-223.
8. Linton, M. F., and S. Fazio. 2001. Class A scavenger receptors, macrophages, and atherosclerosis. Curr. Opin. Lipidol. 12: 489-495.
9. Napoli, C., C. K. Glass, J. L. Witztum, R. Deutsch, F. P. D'Armiento, and W. Palinski. 1999. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood. Fate of Early Lesions in Children (FELIC) Study. Lancet. 354: 1234-1241.
10. Hansson, G. K. 2001. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21: 1876-1890.
11. Libby, P. 2002. Inflammation in atherosclerosis. Nature. 420:868-874.
12. Kannel, W. B., and M. Larson. 1993. Long-term epidemiologic prediction of coronary disease. The Framingham experience. Cardiology. 82: 137-152.
13. Grundy, S. M. 2002. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 105: 2696-2698.
14. McDonnell, D. P. 1999. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 10: 301-311.
15. Kliewer, S. A., S. S. Sundseth, S. A. Jones, P. J. Brown, G. B. Wisely, C. S. Koble, P. Devchand, W. Wahli, T. M. Willson, J. M. Lenhard, and J. M. Lehman. 1997. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA. 94: 4318-4323.
16. Peet, D. J., B. A. Janowski, and D. J. Mangelsdorf. 1998. The LXRs: a new class of oxysterol receptors. Curr. Opin. Genet. Dev. 8: 571-575.
17. Janowski, B. A., M. J. Grogan, S. A. Jones, G. B. Wisely, S. A. Kliewer, E. J. Corey, and D. J. Mangelsdorf. 1999. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. USA. 96: 266-271.
18. Rosenfeld, M. G., and C. K. Glass. 2001. Coregulator codes of transcriptional regulation by nuclear receptors. J. Biol. Chem. 276: 36865-36868.
19. McKenna, N. J., and B. W. O'Malley. 2002. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell. 108: 465-474.
20. Krogsdam, A. M., C. A. Nielsen, S. Neve, D. Holst, T. Helledie, B. Thomsen, C. Bendixen, S. Mandrup, and K. Kristiansen. 2002. Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. Biochem. J. 363: 157-165.
21. Shi, Y., M. Hon, and R. M. Evans. 2002. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl. Acad. Sci. USA. 99: 2613-2618.
22. Wagner, B. L., A. F. Valledor, G. Shao, C. L. Daige, E. D. Bischoff, M. Petrowski, K. Jepsen, S. H. Baek, R. A. Heyman, M. G. Rosenfeld, I. G. Schulman, and C. K. Glass. 2003. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol. 23: 5780-5789.
23. Hu, X., S. Li, J. Wu, C. Xia, and D. S. Lala. 2003. Liver X receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 17: 1019-1026.
24. Glass, C. K., and M. G. Rosenfeld. 2000. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14: 121-141.
25. Perissi, V., A. Aggarwal, C. K. Glass, D. W. Rose, and M. G. Rosenfeld. 2004. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell. 116: 511-526.
26. De Bosscher, K., W. Vanden Berghe, and G. Haegeman. 2003. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24: 488-522.
27. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391: 79-82.
28. Joseph, S. B., A. Castrillo, B. A. Laffitte, D. J. Mangelsdorf, and P. Tontonoz. 2003. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9: 213-219.
29. Laffitte, B. A., S. B. Joseph, R. Walczak, L. Pei, D. C. Wilpitz, J. L. Collins, and P. Tontonoz. 2001. Autoregulation of the human liver X receptor alpha promoter. Mol. Cell. Biol. 21: 7558-7568.
30. Peet, D. J., S. D. Turley, W. Ma, B. A. Janowski, J-M. A. Lobaccaro, R. E. Hammer, and D. J. Mangelsdorf. 1998. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell. 93: 693-704.
31. Repa, J. J., K. E. Berge, C. Pomajzl, J. A. Richardson, H. Hobbs, and D. J. Mangelsdorf. 2002. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277: 18793-18800.
32. Repa, J. J., G. Liang, J. Ou, Y. Bashmakov, J-M. A. Lobaccaro, I. Shimomura, B. Shan, M. S. Brown, J. L. Goldstein, and D. J. Mangelsdorf. 2000. Regulation of mouse sterol regulatory element-binding protein-1 c (SREBP-1c) by oxysterol receptors LXRα and LXRβ. Genes Dev. 14: 2819-2830.
33. Zhang, Y., J. J. Repa, K. Gauthier, and D. J. Mangelsdorf. 2001. Regulation of lipoprotein lipase by the oxysterol receptors, LXR-alpha and LXRbeta. J. Biol. Chem. 276: 43018-43024.
34. Mak, P. A., H. R. Kast-Woelbern, A. M. Anisfeld, and P. A. Edwards. 2002. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 43: 2037-2041.
35. Mak, P. A., B. A. Laffitte, C. Desrumaux, S. B. Joseph, L. K. Curtiss, D. J. Mangelsdorf, P. Tontonoz, and P. A. Edwards. 2002. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in marine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 277: 31900-31908.
36. Schultz, J. R., H. Tu, A. Luk, J. J. Repa, J. C. Medina, L. Li, S. Schwendner, S. Wang, M. Thoolen, D. J. Mangelsdorf, K. D. Lustig, and B. Shan. 2000. Role of LXRs in control of lipogenesis. Genes Dev. 14: 2831-2838.
37. Oram, J. F., and A. M. Vaughan. 2000. ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr. Opin. Lipidol. 11: 253-260.
38. Schmitz, G., W. E. Kaminski, and E. Orso. 2000. ABC transporters in cellular lipid trafficking. Curr. Opin. Lipidol. 11: 493-501.
39. Attie, A. D., J. P. Kastelein, and M. R. Hayden. 2001. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J. Lipid Res. 42: 1717-1726.
40. Young, S. G., and C. J. Fielding. 1999. The ABCs of cholesterol efflux. Nat. Genet. 22: 316-318.
41. McNeish, J., R. J. Aiello, D. Guyot, T. Turi, C. Gabel, C. Aldinger, K. L. Hoppe, M. L. Roach, L. J. Royer, J. de Wet, C. Broccardo, G. Chimini, and O. L. Francone. 2000. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. USA. 97: 4245-4250.
42. Singaraja, R. R., C. Fievet, G. Castro, E. R. James, N. Hennuyer, S. M. Clee, N. Bissada, J. C. Choy, J. C. Fruchart, B. M. McManus, B. Staels, and M. R. Hayden. 2002. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 110: 35-42.
43. Joyce, C. W., M. J. Amar, G. Lambert, B. L. Vaisman, B. Paigen, J. Najib-Fruchart, R. F. Hoyt, Jr., E. D. Neufeld, A. T. Remaley, D. S. Fredrickson, H. B. Brewer, Jr., and S. Santamarina-Fojo. 2002. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc. Natl. Acad. Sci. USA. 99: 407-412.
44. Whitney, K. D., M. A. Watson, B. Goodwin, C. M. Galardi, J. M. Maglich, J. G. Wilson, T. M. Willson, J. L. Collins, and S. A. Kliewer. 2001. Liver X receptor (LXR) regulation of the LXRalpha gene in human macrophages. J. Biol. Chem. 276: 43509-43515.
45. Schwartz, K., R. M. Lawn, and D. P. Wade. 2000. ABC1 gene expression and apoA-1-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274: 794-802.
46. Costet, P., Y. Luo, N. Wang, and A. R. Tall. 2000. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275: 28240-28245.
47. Venkateswaran, A., J. J. Repa, J. M. Lobaccaro, A. Bronson, D. J. Mangelsdorf, and P. A. Edwards. 2000. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J. Biol. Chem. 275: 14700-14707.
48. Laffitte, B. A., J. J. Repa, S. B. Joseph, D. C. Wilpitz, H. R. Kast, D. J. Mangelsdorf, and P. Tontonoz. 2001. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA. 98: 507-512.
49. Klucken, J., C. Buchler, E. Orso, W. E. Kaminski, M. Porsch-Ozcurumez, G. Liebisch, M. Kapinsky, W. Diederich, W. Drobnik, M. Dean, R. Allikmets, and G. Schmitz. 2000. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc. Natl. Acad. Sci. USA. 97: 817-822.
50. Lorkowski, S., M. Kratz, C. Wenner, R. Schmidt, B. Weitkamp, M. Fobker, J. Reinhardt, J. Rauterberg, E. A. Galinski, and P. Cullen. 2001. Expression of the ATP-binding cassette transporter gene ABCG1 (ABC8) in Tangier disease. Biochem. Biophys. Res. Commun. 283: 821-830.
51. Wang, N., D. Lan, W. Chen, F. Matsuura, and A. R. Tall. 2004. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. USA. 101: 9774-9779.
52. Nakamura, K., M. A. Kennedy, A. Baldan, D. D. Bojanic, K. Lyons, and P. A. Edwards. 2004. Expression and regulation of multiple murine ATP-binding cassette transporter G1 mRNAs/isoforms that stimulate cellular cholesterol efflux to high density lipoprotein. J. Biol. Chem. In press.
53. Fu, X., J. G. Menke, Y. Chen, G. Zhou, K. L. MacNaul, S. D. Wright, C. P. Sparrow, and E. G. Lund. 2001. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276: 38378-38387.
54. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, J. Tran, T. K. Tippin, X. Wang, A. J. Lusis, W. A. Hsueh, R. E. Law, J. L. Collins, T. M. Willson, and P. Tontonoz. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99: 7604-7609.
55. Tangirala, R. K., E. D. Bischoff, S. B. Joseph, B. L. Wagner, R. Walczak, B. A. Laffitte, C. L. Daige, D. Thomas, R. A. Heyman, D. J. Mangelsdorf, X. Wang, A. J. Lusis, P. Tontonoz, and I. G. Schulman. 2002. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA. 99: 11896-11901.
56. Castrillo, A., S. B. Joseph, C. Marathe, D. J. Mangelsdorf, and P. Tontonoz. 2003. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 278: 10443-10449.
57. Desvergne, B., and W. Wahli. 1999. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20: 649-688.
58. Willson, T., P. Brown, D. Sternbach, and B. Henke. 2000. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43: 527-550.
59. Issemann, I., and S. Green. 1990. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347: 645-650.
60. Issemann, I., R. A. Prince, J. D. Tugwood, and S. Green. 1993. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. 11: 37-47.
61. Schoonjans, K., M. Watanabe, H. Suzuki, A. Mahfoudi, G. Krey, W. Wahli, P. Grimaldi, B. Staels, T. Yamamoto, and J. Auwerx. 1995. Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270: 19269-19276.
62. Motojima, K., P. Passilly, J. M. Peters, F. J. Gonzalez, and N. Latruffe. 1998. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273: 16710-16714.
63. Rodriguez, J. C., G. Gil-Gomez, F. G. Hegardt, and D. Haro. 1994. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269: 18767-18772.
64. Berthou, L., N. Duverger, F. Emmanuel, S. Langouet, J. Auwerx, A. Guillouzo, J. C. Fruchart, E. Rubin, P. Denefle, B. Staels, and D. Branellec. 1996. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J. Clin. Invest. 97: 2408-2416.
65. Vu-Dac, N., S. Chopin-Delannoy, P. Gervois, E. Bonnelye, G. Martin, J. C. Fruchart, V. Laudet, and B. Staels. 1998. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb-alpha mediate the species-specific regulation of apolipoprotein A-1 expression by fibrates. J. Biol. Chem. 273: 25713-25720.
66. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, H. B. Brewer, J. C. Fruchart, V. Clavey, and B. Staels. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58.
67. Chinetti, G., F. G. Gbaguidi, S. Griglio, Z. Mallat, M. Antonucci, P. Poulain, J. Chapman, J. C. Fruchart, A. Tedgui, J. Najib-Fruchart, and B. Staels. 2000. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 101: 2411-2417.
68. Chinetti, G., S. Lestavel, J. C. Fruchart, V. Clavey, and B. Staels. 2003. Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ. Res. 92: 212-217.
69. Guerre-Millo, M., P. Gervois, E. Raspe, L. Madsen, P. Poulain, B. Derudas, J. M. Herbert, D. A. Winegar, T. M. Willson, J. C. Fruchart, R. K. Berge, and B. Staels. 2000. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275: 16638-16642.
70. Ye, J. M., P. J. Doyle, M. A. Iglesias, D. G. Watson, G. J. Cooney, and E. W. Kraegen. 2001. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 50: 411-417.
71. Chou, C. J., M. Haluzik, C. Gregory, K. R. Dietz, C. Vinson, O. Gavrilova, and M. L. Reitman. 2002. WY14,643, a peroxisome proliferator- activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-Z1P/F-1 mice. J. Biol. Chem. 277: 24484-24489.
72. Marx, N., G. K. Sukhova, T. Collins, P. Libby, and J. Plutzky. 1999. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 99: 3125-3131.
73. Staels, B., W. Koenig, A. Habib, R. Merval, M. Lebret, I. P. Torra, P. Delerive, A. Fadel, G. Chinetti, J. C. Fruchart, J. Najib, J. Maclouf, and A. Tedgui. 1998. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393: 790-793.
74. Marx, N., N. Mackman, U. Schonbeck, N. Yilmaz, V. Hombach, P. Libby, and J. Plutzky. 2001. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation. 103: 213-219.
75. Neve, B. P., D. Corseaux, G. Chinetti, C. Zawadzki, J. C. Fruchart, P. Duriez, B. Staels, and B. Jude. 2001. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 103: 207-212.
76. Shu, H., B. Wong, G. Zhou, Y. Li, J. Berger, J. W. Woods, S. D. Wright, and T. Q. Cai. 2000. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. 267: 345-349.
77. Lee, H., W. Shi, P. Tontonoz, S. Wang, G. Subbanagounder, C. C. Hedrick, S. Hama, C. Borromeo, R. M. Evans, J. A. Berliner, and L. Nagy. 2000. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis of monocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ. Res. 87:516-521.
78. Forman, B. M., J. Chen, and R. M. Evans. 1997. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. USA. 94: 4312-4317.
79. Ziouzenkova, O., S. Perrey, L. Asatryan, J. Hwang, K. L. MacNaul, D. E. Moller, D. J. Rader, A. Sevanian, R. Zechner, G. Hoefler, and J. Plutzky. 2003. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: evidence for an antiinflammatory role for lipoprotein lipase. Proc. Natl. Acad. Sci. USA. 100: 2730-2735.
80. Robins, S. J., D. Collins, J. T. Wittes, V. Papademetriou, P. C. Deedwania, E. J. Schaefer, J. R. McNamara, M. L. Kashyap, J. M. Hershman, L. F. Wexler, and H. B. Rubins. 2001. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial. J. Am. Med. Assoc. 285: 1585-1591.
81. Robins, S. J., H. B. Rubins, F. H. Faas, E. J. Schaefer, M. B. Elam, J. W. Anderson, and D. Collins. 2003. Insulin resistance and cardiovascular events with low HDL cholesterol. The Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care. 26: 1513-1517.
82. Tordjman, K., C. Bernal-Mizrachi, L. Zemany, S. Weng, C. Feng, F. Zhang, T. C. Leone, T. Coleman, D. P. Kelly, and C. F. Semenkovich. 2001. PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107: 1025-1034.
83. Fu, T., P. Kashireddy, and J. Borensztajn. 2003. The peroxisome- proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J. 373: 941-947.
84. Claudel, T., M. D. Leibowitz, C. Fievet, A. Tailleux, B. Wagner, J. J. Repa, G. Torpier, J. M. Lobaccaro, J. R. Paterniti, D. J. Mangelsdorf, R. A. Heyman, and J. Auwerx. 2001. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. USA. 98: 2610-2615.
85. Duez, H., Y. S. Chao, M. Hernandez, G. Torpier, P. Poulain, S. Mundt, Z. Mallat, E. Teissier, C. A. Burton, A. Tedgui, J. C. Fruchart, C. Fievet, S. D. Wright, and B. Staels. 2002. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J. Biol. Chem. 277: 48051-48057.
86. Li, A. C., C. J. Binder, A. Gutierrez, K. K. Brown, C. R. Plotkin, J. W. Pattison, A. F. Valledor, R. A. Davis, T. M. Willson, J. L. Witztum, W. Palinski, and C. K. Glass. 2004. Differential inhibition of macrophage foam cell formation and atherosclerosis in mice by PPAR a, b/d, and g. J. Clin. Invest. In press.
87. Chinetti, G., S. Griglio, M. Antonucci, I. P. Torra, P. Delerive, Z. Majd, J-C. Fruchart, J. Chapman, J. Najib, and B. Staels. 1998. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273: 25573-25580.
88. Reardon, C. A., and G. S. Getz. 2001. Mouse models of atherosclerosis. Curr. Opin. Lipidol. 12: 167-173.
89. Kliewer, S. A., J. M., Lehmann, M. V. Milburn, and T. M. Willson. 1999. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog. Horm. Res. 54: 345-368.
90. Nagy, L., P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma. Cell. 93: 229-240.
91. 2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83: 803-812.
92. Bell-Parikh, L. C., T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald. 2003. Biosynthesis of 15-deoxy-deltal2,14-PGJ2 and the ligation of PPARgamma. J. Clin. Invest. 112: 945-955.
93. Huang, J. T., J. S. Welch, M. Ricote, C. J. Binder, T. M. Willson, C. Kelly, J. L. Witztum, C. D. Funk, D. Conrad, and C. K. Glass. 1999. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature. 400: 378-382.
94. Tontonoz, P., E. Hu, R. A. Graves, A. I. Budavari, and B. M. Spiegelman. 1994. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8: 1224-1234.
95. Zhu, Y., C. Qi, J. R. Korenberg, X. N. Chen, D. Noya, M. S. Rao, and J. K. Reddy. 1995. Structural organization of mouse peroxisome proliferator- activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc. Natl. Acad. Sci. USA. 92: 7921-7925.
96. Tontonoz, P., E. Hu, and B. M. Spiegelman. 1994. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 79: 1147-1156.
97. Barak, Y., M. C. Nelson, E. S. Ong, Y. Z. Jones, P. Ruiz-Lozano, K. R. Chien, A. Koder, and R. M. Evans. 1999. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4: 585-595.
98. Kubota, N., Y. Terauchi, H. Miki, H. Tamemoto, T. Yamauchi, K. Komeda, S. Satoh, R. Nakano, C. Ishii, T. Sugiyama, K. Eto, Y. Tsubamaoto, A. Okuno, K. Murakami, H. Sekihara, G. Hasegawa, M. Naito, Y. Toyoshima, S. Tanaka, K. Shiota, T. Kitamura, T. Fujita, O. Ezaki, S. Aizawa, R. Nagai, K. Tobe, S. Kimura, and T. Kadowaki. 1999. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4: 597-609.
99. Rosen, E. D., P. Sarraf, A. E. Troy, G. Bradwin, K. Moore, D. A. Milstone, B. M. Spiegelman, and R. M. Mortensen. 1999. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4: 611-617.
100. Lehmann, J. M., L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma). J. Biol. Chem. 270: 12953-12956.
101. Gurnell, M., D. B. Savage, V. K. Chatterjee, and S. O'Rahilly. 2003. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J. Clin. Endocrinol. Metab. 88: 2412-2421.
102. He, W., Y. Barak, A. Hevener, P. Olson, D. Liao, J. Le, M. Nelson, E. Ong, J. M. Olefsky, and R. M. Evans. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. USA. 100: 15712-15717.
103. Hevener, A. L., W. He, Y. Barak, J. Le, G. Bandyopadhyay, P. Olson, J. Wilkes, R. M. Evans, and J. Olefsky. 2003. Muscle-specific PPARg deletion causes insulin resistance. Nat. Med. 9: 1491-1497.
104. Norris, A. W., L. Chen, S. J. Fisher, I. Szanto, M. Ristow, A. C. Jozsi, M. F. Hirshman, E. D. Rosen, L. J. Goodyear, F. J. Gonzalez, B. M. Spiegelman, and C. R. Kahn. 2003. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112: 608-618.
105. Gavrilova, O., M. Haluzik, K. Matsusue, J. J. Cutson, L. Johnson, K. R. Dietz, C. J. Nicol, C. Vinson, F. J. Gonzalez, and M. L. Reitman. 2003. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278: 34268-34276.
106. Wu, Z., Y. Xie, R. F. Morrison, N. L. Bucher, and S. R. Farmer. 1998. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest. 101: 22-32.
107. Lefebvre, A-M., J. Peinado-Onsurbe, I. Leitersdorf, M. R. Briggs, J. R. Paterniti, J-C. Fruchart, C. Fievet, J. Auwerx, and B. Staels. 1997. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler. Thromb. 17: 1756-1764.
108. Brun, R. P., P. Tontonoz, B. M. Forman, R. Ellis, J. Chen, R. M. Evans, and B. M. Spiegelman. 1996. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 10: 974-984.
109. Maeda, N., M. Takahashi, T. Funahashi, S. Kihara, H. Nishizawa, K. Kishida, H. Nagaretani, M. Matsuda, R. Komuro, N. Ouchi, H. Kuriyama, K. Hotta, T. Nakamura, I. Shimomura, and Y. Matsuzawa. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50: 2094-2099.
110. Yamauchi, T., J. Kamon, H. Waki, K. Murakami, K. Motojima, K. Komeda, T. Ide, N. Kubota, Y. Terauchi, K. Tobe, H. Miki, A. Tsuchida, Y. Akanuma, R. Nagai, S. Kimura, and T. Kadowaki. 2001. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276: 41245-41254.
111. Dandona, P., A. Aljada, and A. Bandyopadhyay. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25: 4-7.
112. Daynes, R. A., and D. C. Jones. 2002. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2: 748-759.
113. Peraldi, P., M. Xu, and B. M. Spiegelman. 1997. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J. Clin. Invest. 100: 1863-1869.
114. Haffner, S. M., A. S. Greenberg, W. M. Weston, H. Chen, K. Williams, and M. I. Freed. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106: 679-684.
115. Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391: 82-86.
116. Ricote, M., A. F. Valledor, and C. K. Glass. 2004. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24: 230-239.
117. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans. 2001. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52.
118. 2 inhibits multiple steps in the NF-kB signaling pathway. Proc. Natl. Acad. Sci. USA. 97: 4844-4849.
119. Rossi, A., P. Kapahi, G. Natoli, T. Takahashi, Y. Chen, M. Karin, and M. G. Santoro. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature. 403: 103-108.
120. Welch, J. S., M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass. 2003. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl. Acad. Sci. USA. 100: 6712-6717.
121. Wellen, K. E., and G. S. Hotamisligil. 2003. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112: 1785-1788.
122. Xu, H., G. T. Barnes, Q. Yang, G. Tan, D. Yang, C. J. Chou, J. Sole, A. Nichols, J. S. Ross, L. A. Tartaglia, and H. Chen. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112: 1821-1830.
123. Tontonoz, P., L. Nagy, J. G. A. Alvarez, V. A. Thomazy, and R. M. Evans. 1998. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93: 241-252.
124. Febbraio, M., D. P. Hajjar, and R. L. Silverstein. 2001. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J. Can. Invest. 108: 785-791.
125. Liang, C. P., S. Han, H. Okamoto, R. Carnemolla, I. Tabas, D. Accili, and A. R. Tall. 2004. Increased CD36 protein as a response to defective insulin signaling in macrophages. J. Clin. Invest. 113: 764-773.
126. Chawla, A., W. A. Boisvert, C. H. Lee, B. A. Laffitte, Y. Barak, S. B. Joseph, D. Liao, L. Nagy, P. A. Edwards, L. K. Curtiss, R. M. Evans, and P. Tontonoz. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7: 161-171.
127. Szanto, A., S. Benko, I. Szatmari, B. L. Balint, I. Furtos, R. Ruhl, S. Molnar, L. Csiba, R. Garuti, S. Calandra, H. Larsson, U. Diczfalusy, and L. Nagy. 2004. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol. Cell. Biol. 24:8154-8166.
128. Minamikawa, J., S. Tanaka, M. Yamauchi, D. Inoue, and H. Koshiyama. 1998. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 83: 1818-1820.
129. Koshiyama, H., D. Shimono, N. Kuwamura, J. Minamikawa, and Y. Nakamura. 2001. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 86: 3452-3456.
130. Li, A., K. Brown, M. Silvestre, T. Willson, W. Palinski, and C. Glass. 2000. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106: 523-531.
131. Collins, A. R., W. P. Meehan, U. Kintscher, S. Jackson, S. Wakino, G. Noh, W. Palinski, W. A. Hsueh, and R. E. Law. 2001. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21: 365-371.
132. Chen, Z., S. Ishibashi, S. Perrey, J. Osuga, T. Gotoda, T. Kitamine, Y. Tamura, H. Okazaki, N. Yahagi, Y. Iizuka, F. Shionoiri, K. Ohashi, K. Harada, H. Shimano, R. Nagai, and N. Yamada. 2001. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21: 372-377.
133. Yagu, H., T. Kitamine, J. Osuga, R. Tozawa, Z. Chen, Y. Kaji, T. Oka, S. Perrey, Y. Tamura, K. Ohyashi, H. Okazaki, N. Yahagi, F. Shionoiri, Y. Iizuka, K. Harada, H. Shimano, H. Yamashita, T. Gotoda, N. Yamada, and S. Ishibashi. 2000. Absence of ACAT-1 at tenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. J. Biol. Chem. 275: 21324-21330.
134. Fazio, S., A. S. Major, L. L. Swift, L. A. Gleaves, M. Accad, M. F. Linton, and R. V. Farese, Jr. 2001. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J. Clin. Invest. 107: 163-171.
135. Kusunoki, J., D. K. Hansoty, K. Aragane, J. T. Fallon, J. J. Badimon, and E. A. Fisher. 2001. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 103: 2604-2609.
136. Sauerberg, P., I. Pettersson, L. Jeppesen, P. S. Bury, J. P. Mogensen, K. Wassermann, C. L. Brand, J. Sturis, H. F. Woldike, J. Fleckner, A. S. Andersen, S. B. Mortensen, L. A. Svensson, H. B. Rasmussen, S. V. Lehmann, Z. Polivka, K. Sindelar, V. Panajotova, L. Ynddal, and E. M. Wulff. 2002. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 45: 789-804.
137. Ye, J. M., M. A. Iglesias, D. G. Watson, B. Ellis, L. Wood, P. B. Jensen, R. V. Sorensen, P. J. Larsen, G. J. Cooney, K. Wassermann, and E. W. Kraegen. 2003. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am. J. Physiol. Endocrinol. Metab. 284: E531-E540.
138. Zuckerman, S. H., R. F. Kauffman, and G. F. Evans. 2002. Peroxisome proliferator-activated receptor alpha,gamma coagonist LY465608 inhibits macrophage activation and atherosclerosis in apolipoprotein E knockout mice. Lipids. 37: 487-494.
139. Kliewer, S. A., B. M. Forman, B. Blumberg, E. S. Ong, U. Borgmeyer, D. J. Mangelsdorf, K. Umesono, and R. M. Evans. 1994. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. USA. 91: 7355-7359.
140. Wang, Y. X., C. H. Lee, S. Tiep, R. T. Yu, J. Ham, H. Kang, and R. M. Evans. 2003. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell. 113: 159-170.
141. Oliver, W. R., Jr., J. L. Shenk, M. R. Snaith, C. S. Russell, K. D. Plunket, N. L. Bodkin, M. C. Lewis, D. A. Winegar, M. L. Sznaidman, M. H. Lambert, H. E. Xu, D. D. Sternbach, S. A. Kliewer, B. C. Hansen, and T. M. Willson. 2001. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA. 98: 5306-5311.
142. Michalik, L., B. Desvergne, N. S. Tan, S. Basu-Modak, P. Escher, J. Rieusset, J. M. Peters, G. Kaya, F. J. Gonzalez, J. Zakany, D. Metzger, P. Chambon, D. Duboule, and W. Wahli. 2001. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell Biol. 154: 799-814.
143. Tan, N. S., L. Michalik, N. Noy, R. Yasmin, C. Pacot, M. Heim, B. Fluhmann, B. Desvergne, and W. Wahli. 2001. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev. 15: 3263-3277.
144. Vosper, H., L. Patel, T. L. Graham, G. A. Khoudoli, A. Hill, C. H. Macphee, I. Pinto, S. A. Smith, K. E. Suckling, C. R. Wolf, and C. N. Palmer. 2001. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J. Biol. Chem. 276: 44258-44265.
145. Chawla, A., C. H. Lee, Y. Barak, W. He, J. Rosenfeld, D. Liao, J. Han, H. Kang, and R. M. Evans. 2003. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc. Natl. Acad. Sci. USA. 100: 1268-1273.
146. Rival, Y., N. Beneteau, T. Taillandier, M. Pezet, E. Dupont-Passelaigue, J. F. Patoiseau, D. Junquero, F. C. Colpaert, and A. Delhon. 2002. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435: 143-151.
147. Lee, C. H., A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans. 2003. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science. 302: 453-457.